In a couple of years, Amgen, Inc. (NASDAQ:AMGN) will have to face the music when the patent for its $4 billion a year drug, Neulasta, expires in the U.S. and Europe.
Keep Reading →
September 12 - News
When most biotech investors think of cancer treatments, they tend to think of large established players like Roche and Amgen.
Keep Reading →
September 12 - News
A couple of recent events got me thinking about price elasticity and how a savvy investor can capitalize on producers of inelastic products.
Keep Reading →
September 10 - News
Since the time covered in last week's update, Microsoft Corporation (NASDAQ:MSFT) lost more in market value for the real-money Inflation-Protected Income Growth portfolio ...
Keep Reading →
September 10 - News
In the 21st century investor’s toolkit, there are a multitude of metrics investors can use to track Mr. Market.
Keep Reading →
September 5 - News
This past week has been fairly brutal to stocks as the situation in Syria deteriorated and American saber-rattling suggested that a military intervention may be right around the...
Keep Reading →
September 4 - News
Allergan, Inc. (NYSE:AGN), the diversified health care giant best known for Botox, boasts an impressive portfolio of products.
Keep Reading →
August 30 - News
Shares of Perrigo Company (NYSE:PRGO), one of the world's largest health care suppliers, slid with the broader market on Aug.
Keep Reading →
August 27 - News
After a second offer, Amgen, Inc. (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc.
Keep Reading →
August 27 - News
Dividend investors would be wise to focus not just on a stock's current yield, but also on the long-term growth potential of its dividends.
Keep Reading →
August 27 - Dividend Stocks, News
The wild swings in the market continued this past week, aided and abetted by both Goldman Sachs' trading glitch and the unexpected mid-session Nasdaq shutdown.
Keep Reading →
August 27 - News
Judging by the numbers, Galena Biopharma Inc (NASDAQ:GALE) isn't exactly a stock many would call great.
Keep Reading →
August 26 - News
A finale has at last arrived for the biotech drama of summer 2013. Amgen, Inc. (NASDAQ:AMGN) announced yesterday that it will buy Onyx Pharmaceuticals, Inc.
Keep Reading →
August 26 - News
In the eyes of many of your fellow readers, hedge funds are seen as useless, old financial vehicles of an era lost to time.
Keep Reading →
August 26 - News
Breast cancer claims more than 40,000 lives in the United States annually and is one of the leading causes of death for females globally.
Keep Reading →
August 23 - News
Like most pharma companies, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)'s stock price generally trades akin to the actions of a roller coaster.
Keep Reading →
August 22 - News
Bernard Horn, the manager of Polaris Capital Management, is a former employee of MDT Advisers.
Keep Reading →
August 19 - Hedge Funds
It's a disease that doesn't often find itself in the spotlight, but multiple sclerosis is quickly becoming an ailment that drugmakers are focusing their efforts on to make a quality...
Keep Reading →
August 19 - News
Sometimes the market drops, as do even the greatest companies within it.
Keep Reading →
August 13 - News
Pharmaceutical companies are always looking for competitive advantages.
Keep Reading →
August 13 - News
Will generic pharmaceutical makers like Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Perrigo Company (NYSE:PRGO) continue to be a value play after Obamacare kicks...
Keep Reading →
August 12 - News
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has been stuck is share purgatory for a number of years.
Keep Reading →
August 6 - News
Maybe Texas just needs to fire up Ol' Sparky again.
Keep Reading →
August 5 - News
The investing waters can get pretty choppy from time to time with a developmental stage company. A look at the five-year chart of Momenta Pharmaceuticals, Inc.
Keep Reading →
August 2 - News
Hidden beneath all the numbers and metrics in Biogen Idec Inc (NASDAQ:BIIB)'s recent earnings report is a key confirmation of a shifting market in the treatment of multiple sclerosis...
Keep Reading →
August 1 - News
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) hardly gets the attention it deserves.
Keep Reading →
August 1 - News
With the SPDR S&P Biotech Index up 29% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
July 29 - News
The United States Court of Appeals is making this one miserable summer for Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
Keep Reading →
July 29 - News
The recent rally in shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) may suggest investors are regaining some confidence in this pharmaceutical manufacturer.
Keep Reading →
July 23 - News
The medical community certainly spends a lot of time and money researching treatments for cardiovascular disease and cancer.
Keep Reading →
July 15 - News
The real-money Inflation-Protected Income Growth portfolio just finished an astonishingly strong week, rising by more than $1,080 since the prior week's update to close with a...
Keep Reading →
July 15 - News
VIVUS, Inc. (NASDAQ:VVUS) has found an Italian to help it out.
Keep Reading →
July 10 - News
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown.
Keep Reading →
July 10 - News
Recently, I enjoyed an article contributed by Adam Feuerstein ("AF article") regarding Antares Pharma Inc (NASDAQ:ATRS) and its transformational product Otrexup.
Keep Reading →
July 5 - News
It's hard to believe, but 2013 is already more than halfway over. This year has been a good one for many pharmaceutical stocks -- at least so far.
Keep Reading →
July 3 - News
Amgen, Inc. (NASDAQ:AMGN) has gone up a lot in share price over the last few years. Amgen, Inc.
Keep Reading →
July 1 - News
Cheap generic versions of Pfizer Inc. (NYSE:PFE)'s Viagra are coming to Europe, according the generic-drug maker Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
Keep Reading →
June 27 - News
A double-digit drop for Amgen, Inc. (NASDAQ:AMGN) stock over the past couple of months has likely left a bad taste in the mouths of shareholders.
Keep Reading →
June 25 - News
The healthcare sector has always been a subject of great interest to investors and analysts alike.
Keep Reading →
June 21 - News
A new Supreme Court ruling presents pharmaceutical companies with a tough choice -- stop paying generic-drug producers to withhold generic options from the market, or risk getting...
Keep Reading →
June 20 - News
Cancer is one of the deadliest challenges that humans face today. Different forms of cancer have taken millions of lives all around the world.
Keep Reading →
June 19 - News
Generic-drug makers are always on the hunt for the next branded drug to take down.
Keep Reading →
June 13 - News
Generic producers are often regarded as the safer players within BioPharma.
Keep Reading →
June 13 - News
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been on an acquisition spree. Its latest purchase is Bausch + Lomb in an all-cash deal worth $8.7 billion.
Keep Reading →
June 12 - News
With one product already on the market, one recently approved and four more in various stages of clinical development, Biogen Idec Inc.
Keep Reading →
June 12 - News
The real-money Inflation-Protected Income Growth portfolio rose in value by a bit more than $245 since last week's update to end the week at $34,593.13.
Keep Reading →
June 10 - News
In late April, biotechnology firm Opko Health Inc.
Keep Reading →
June 6 - News
Editor's Note: Related tickers: Infosys Ltd ADR (NYSE:INFY), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), Marathon Petroleum Corp (NYSE:MPC), VIVUS, Inc.
Keep Reading →
June 5 - Hedge Funds
Tucked away inside Obamacare are 18 pages that could create a new $20 billion-per-year market.
Keep Reading →
June 4 - News
